

# The anti-cancer agents lenalidomide and pomalidomide function of T regulatory cells

Cancer Immunology, Immunotherapy

58, 1033-1045

DOI: [10.1007/s00262-008-0620-4](https://doi.org/10.1007/s00262-008-0620-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Lenalidomide in multiple myeloma. Expert Review of Anticancer Therapy, 2009, 9, 1559-1570.	1.1	4
2	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4563-4569.	0.8	213
3	T-regulatory cell modulation: the future of cancer immunotherapy?. British Journal of Cancer, 2009, 100, 1697-1703.	2.9	91
4	Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Experimental Hematology, 2009, 37, 791-798.	0.2	90
5	IMiDs induce pleiotropic anti-cancer effects. Memo - Magazine of European Medical Oncology, 2009, 2, 10-12.	0.3	1
6	Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). British Journal of Cancer, 2009, 101, 803-812.	2.9	39
7	Novel therapies for relapsed myeloma. Hematology American Society of Hematology Education Program, 2009, 2009, 578-586.	0.9	22
8	Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia and Lymphoma, 2009, 50, 1860-1864.	0.6	53
9	Drug-mediated and cellular immunotherapy in multiple myeloma. Immunotherapy, 2010, 2, 243-255.	1.0	13
10	Recent advances of IMiDs in cancer therapy. Current Opinion in Oncology, 2010, 22, 579-585.	1.1	30
11	Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica, 2010, 95, 406-414.	1.7	48
12	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood, 2010, 116, 3227-3237.	0.6	202
13	Regulatory T Cell as a Target for Cancer Therapy. Archivum Immunologiae Et Therapiae Experimentalis, 2010, 58, 179-190.	1.0	29
14	A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro. Molecular Biology Reports, 2010, 37, 1801-1814.	1.0	29
15	Novel agents for B-cell non-Hodgkin lymphoma: Science and the promise. Blood Reviews, 2010, 24, 69-82.	2.8	13
16	Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. British Journal of Haematology, 2010, 148, 948-950.	1.2	55
17	Development of target-specific treatments in multiple myeloma. British Journal of Haematology, 2010, 151, 3-15.	1.2	22
18	Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 2010, 24, 22-32.	3.3	505

#	ARTICLE	IF	CITATIONS
19	Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. <i>Leukemia</i> , 2010, 24, 592-600.	3.3	36
20	Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. <i>Journal of Oncology</i> , 2010, 2010, 1-8.	0.6	13
21	Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or treated with immunomodulatory agents. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010005.	0.5	12
22	Recent Pharmacological Advances: Focus on Small-cell Lung Cancer. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S44.	0.4	1
23	Lenalidomide-Induced Acute Interstitial Nephritis. <i>Oncologist</i> , 2010, 15, 961-964.	1.9	23
24	The potential of immunomodulatory drugs in the treatment of solid tumors. <i>Future Oncology</i> , 2010, 6, 1479-1484.	1.1	11
25	Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 61-95.	0.7	32
26	Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-12.	3.0	41
27	Cost-effectiveness of lenalidomide in multiple myeloma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 229-238.	0.7	7
28	Lenalidomide in multiple myeloma: current role and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 829-842.	0.9	12
29	Reduced-intensity Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Concise Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 247-252.	0.2	8
30	How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 779-793.	1.9	9
31	Translational development of vaccination strategies in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 295-304.	0.7	7
32	Spontaneous Autologous Graft-versus-Host Disease in Plasma Cell Myeloma Autograft Recipients: Flow Cytometric Analysis of Hematopoietic Progenitor Cell Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 970-978.	2.0	42
33	Pomalidomide therapy for myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 691-700.	1.9	29
34	Mechanisms of Anti-Cancer Effects of <i>Vernonia amygdalina</i> Leaf Extract. <i>American Journal of Pharmacology and Toxicology</i> , 2011, 6, 76-79.	0.7	0
35	Distribution, Arrangement and Interconnectedness of Cell Surface Receptor sites in the body of an Organism. <i>OnLine Journal of Biological Sciences</i> , 2011, 11, 101-104.	0.2	0
36	Lenalidomide-Associated ITP. <i>Case Reports in Hematology</i> , 2011, 2011, 1-4.	0.3	2

#	ARTICLE	IF	CITATIONS
38	Immunotherapy for Myeloproliferative Neoplasms (MPN). <i>Current Cancer Drug Targets</i> , 2011, 11, 72-84.	0.8	7
39	Quantitative and functional analyses of CD4 <sup>+</sup> CD25 <sup>+</sup> FoxP3 <sup>+</sup> regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. <i>British Journal of Haematology</i> , 2011, 153, 139-143.	1.2	17
40	A review of the history, properties, and use of the immunomodulatory compound lenalidomide. <i>Annals of the New York Academy of Sciences</i> , 2011, 1222, 76-82.	1.8	67
41	Multiple myeloma patients at peripheral blood stem cell harvest: Restricted usage of TCR beta variable families. <i>Clinical Immunology</i> , 2011, 138, 67-76.	1.4	1
42	Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide. <i>Clinical Immunology</i> , 2011, 138, 201-211.	1.4	14
43	Current status and future applications of cellular therapies for cancer. <i>Immunotherapy</i> , 2011, 3, 507-516.	1.0	26
44	The Immune Microenvironment of Myeloma. <i>Cancer Microenvironment</i> , 2011, 4, 313-323.	3.1	44
45	Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. <i>American Journal of Hematology</i> , 2011, 86, 343-345.	2.0	27
46	Treatment with lenalidomide modulates T cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2011, 117, 3999-4008.	2.0	71
47	Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. <i>Future Oncology</i> , 2011, 7, 135-143.	1.1	6
48	Lenalidomide in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 273-286.	1.9	7
49	Lenalidomide – Current Understanding of Mechanistic Properties. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 315-326.	0.9	29
50	Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report. <i>Journal of Clinical Oncology</i> , 2011, 29, 316-323.	0.8	61
51	Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma. <i>Journal of Immunology</i> , 2011, 187, 1047-1056.	0.4	33
52	Immune Recovery after Cyclophosphamide Treatment in Multiple Myeloma: Implication for Maintenance Immunotherapy. <i>Bone Marrow Research</i> , 2011, 2011, 1-7.	1.7	34
53	Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2011, 3, 3449-3460.	1.7	2
54	Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-13.	3.3	36
55	Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses. <i>Clinical Cancer Research</i> , 2012, 18, 1426-1434.	3.2	102

#	ARTICLE	IF	CITATIONS
56	Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 3389-3398.	0.9	19
57	CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2013-2015.	0.8	22
58	Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7275.	0.6	8
59	Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies. <i>Advances in Hematology</i> , 2012, 2012, 1-9.	0.6	50
60	Lenalidomide in Diffuse Large B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-8.	0.6	18
61	Comment on "Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome". <i>Journal of Immunology</i> , 2012, 189, 4199.1-4199.	0.4	0
62	Response to Comment on "Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome". <i>Journal of Immunology</i> , 2012, 189, 4199.2-4200.	0.4	0
63	Immunomodulatory Drugs and Active Immunotherapy for Chronic Lymphocytic Leukemia. <i>Cancer Control</i> , 2012, 19, 54-67.	0.7	25
64	Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. <i>British Journal of Haematology</i> , 2012, 159, 154-163.	1.2	85
65	Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMiDs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1075-1087.	1.9	19
66	Emerging biological insights and novel treatment strategies in multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 407-438.	1.0	13
67	Multiple myeloma and immunomodulation: regulating the regulatory cells. <i>Leukemia and Lymphoma</i> , 2012, 53, 1253-1254.	0.6	6
68	A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q del myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2012, 53, 779-788.	0.6	15
69	Immunomodulatory agents in myelofibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1141-1154.	1.9	14
70	Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice. <i>AAPS Journal</i> , 2012, 14, 872-882.	2.2	29
71	Mechanism of immunomodulatory drugs in multiple myeloma. <i>Leukemia Research</i> , 2012, 36, 1218-1224.	0.4	23
72	Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma. <i>Immunotherapy</i> , 2012, 4, 1043-1051.	1.0	9
74	Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma. <i>PLoS ONE</i> , 2012, 7, e47077.	1.1	101

#	ARTICLE	IF	CITATIONS
75	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Cancer Management and Research</i> , 2012, 4, 253.	0.9	28
76	Regulatory Cells and Multiple Myeloma. , 2012, , .		1
77	Cellular immunotherapy using dendritic cells against multiple myeloma. <i>The Korean Journal of Hematology</i> , 2012, 47, 17.	0.7	9
78	Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. <i>Prostate</i> , 2012, 72, 487-498.	1.2	13
79	T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis. <i>Cancer Research</i> , 2012, 72, 2162-2171.	0.4	663
80	The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors. <i>Seminars in Oncology</i> , 2012, 39, 323-339.	0.8	132
81	The Potential Beneficial Effects of Drugs on the Immune Response to Vaccination. <i>Seminars in Oncology</i> , 2012, 39, 340-347.	0.8	10
82	Immune Reconstitution in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 13-20.	1.2	23
83	The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2012, 17, 164-173.	2.2	14
84	Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 207-235.	0.9	84
85	T-Cell Lymphomas. , 2013, , .		1
86	How lenalidomide is changing the treatment of patients with multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S23-S35.	2.0	24
87	Pomalidomide in the treatment of relapsed multiple myeloma. <i>Future Oncology</i> , 2013, 9, 939-948.	1.1	3
88	Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 360-365.	1.0	47
89	Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S5-S13.	2.0	17
90	Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 683-687.	0.6	236
91	Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. <i>Blood Cancer Journal</i> , 2013, 3, e143-e143.	2.8	97
92	Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma. <i>Seminars in Oncology</i> , 2013, 40, 618-633.	0.8	24

#	ARTICLE	IF	CITATIONS
93	Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1368-1373.	2.0	29
94	Pomalidomide: New immunomodulatory agent with potent antiproliferative effects. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S36-S44.	2.0	30
95	Immunomodulatory agents changing the landscape of multiple myeloma treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S1-S4.	2.0	3
96	Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. <i>Leukemia Research</i> , 2013, 37, 1440-1444.	0.4	25
97	Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma. <i>Experimental Hematology</i> , 2013, 41, 231-240.	0.2	6
98	Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. <i>Cellular and Molecular Immunology</i> , 2013, 10, 222-229.	4.8	139
99	Perspectives in the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, S1-S22.	1.4	18
100	Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. <i>Oncogene</i> , 2013, 32, 4191-4202.	2.6	74
101	Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy. <i>Immunotherapy</i> , 2013, 5, 621-637.	1.0	17
102	Enhanced cross-priming of naive CD8 <sup>+</sup> T cells by dendritic cells treated by the LMID immunomodulatory compounds lenalidomide and pomalidomide. <i>Immunology</i> , 2013, 139, 377-385.	2.0	76
103	Novel lenalidomide-based combinations for treatment of multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 9-20.	2.0	11
104	Lenalidomide enhances anti-myeloma cellular immunity. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 39-49.	2.0	149
105	Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 335-341.	0.9	28
106	Fatal Cardiac and Renal Allograft Rejection With Lenalidomide Therapy for Light-Chain Amyloidosis. <i>American Journal of Transplantation</i> , 2013, 13, 2730-2733.	2.6	21
107	Trial Watch: Lenalidomide-based immunochemotherapy. <i>Oncolimmunology</i> , 2013, 2, e26494.	2.1	50
108	Risk of secondary primary malignancies in maintenance therapy for multiple myeloma. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 339-347.	0.7	1
109	Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?. <i>Current Cancer Drug Targets</i> , 2013, 13, 30-47.	0.8	10
110	Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. <i>Current Biomarker Findings</i> , 0, , 17.	0.4	1

#	ARTICLE	IF	CITATIONS
111	Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e80437.	1.1	28
112	Regulatory T Cells in Allogeneic Stem Cell Transplantation. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-9.	3.3	24
113	Lenalidomide and Chronic Lymphocytic Leukemia. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	20
114	Cellular Immunotherapy Using Dendritic Cells in Multiple Myeloma: New Concept to Enhance Efficacy. , 0, , .		0
115	Pomalidomide for the treatment of relapsedâ€“refractory multiple myeloma: a review of biological and clinical data. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 499-510.	1.1	19
116	Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. <i>Acta Biochimica Et Biophysica Sinica</i> , 2014, 46, 240-253.	0.9	47
117	Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 325.	0.4	2
118	Immunotherapy for multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 91-96.	1.0	12
119	Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. <i>Leukemia</i> , 2014, 28, 1573-1585.	3.3	108
120	Pomalidomide for multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 719-731.	1.0	17
121	Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. <i>Leukemia and Lymphoma</i> , 2014, 55, 1090-1098.	0.6	66
122	Advances in Tumor Immunology and Immunotherapy. , 2014, , .		2
123	Lenalidomideâ€“based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 795-802.	2.0	63
124	Dendritic Cell Cancer Vaccines: From the Bench to the Bedside. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0024.	0.4	11
125	Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1355-1365.	3.2	116
126	Stimulation of invariant natural killer T cells by Î±â€“Galactosylceramide activates the <sc>JAK</sc>-<sc>STAT</sc> pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model. <i>British Journal of Haematology</i> , 2014, 167, 651-663.	1.2	12
127	Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma. <i>Bone Marrow Research</i> , 2014, 2014, 1-7.	1.7	14
128	A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 302-304.	0.5	24



#	ARTICLE	IF	CITATIONS
129	Immune-Modulating Drugs and Hypomethylating Agents to Prevent or Treat Relapse after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 168-172.	2.0	7
130	Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 517-524.	0.4	18
131	Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells. <i>Cancer Research</i> , 2014, 74, 2663-2668.	0.4	123
132	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2014, , .	1.8	4
133	Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 41-62.	1.3	112
134	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. <i>Leukemia</i> , 2014, 28, 993-1000.	3.3	92
135	Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. <i>Leukemia</i> , 2014, 28, 329-337.	3.3	51
137	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). <i>Leukemia</i> , 2014, 28, 525-542.	3.3	214
138	Immunomodulatory agents lenalidomide and pomalidomide coâ€stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp>karos and <scp>A</scp>iolos via modulation of the <scp>E</scp>3 ubiquitin ligase complex <scp>CRL</scp>4<scp><sup>CRBN</sup></scp>. <i>British Journal of Haematology</i> , 2014, 164, 811-821.	1.2	505
139	Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. <i>Clinical and Experimental Immunology</i> , 2014, 177, 439-453.	1.1	50
140	Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1023-1036.	2.0	35
141	Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician. <i>Journal of Clinical Oncology</i> , 2014, 32, 3039-3047.	0.8	115
142	Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. , 2014, 144, 338-348.		47
143	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1089-1108.	0.5	1
144	Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma. <i>Journal of Immunotherapy</i> , 2015, 38, 330-339.	1.2	65
145	Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles. <i>Viruses</i> , 2015, 7, 5780-5791.	1.5	24
146	Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. <i>Blood</i> , 2015, 125, 4042-4051.	0.6	103
147	Cereblon binding molecules in multiple myeloma. <i>Blood Reviews</i> , 2015, 29, 329-334.	2.8	49

#	ARTICLE	IF	CITATIONS
148	Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 787-804.	1.1	5
149	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. <i>Leukemia and Lymphoma</i> , 2015, 56, 1671-1676.	0.6	22
150	Cancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape. , 2015, , 195-208.		2
151	Tumor-induced CD14+HLA-DR <sup>hi</sup> /low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 389-399.	2.0	79
152	Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 111-124.	1.7	17
153	CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma. <i>Human Gene Therapy</i> , 2015, 26, 498-505.	1.4	56
154	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. <i>Nature Medicine</i> , 2015, 21, 914-921.	15.2	728
155	Vaccination of multiple myeloma: Current strategies and future prospects. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 339-354.	2.0	20
156	Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy. <i>Annals of Medicine</i> , 2015, 47, 209-217.	1.5	20
157	Lenalidomide in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 491-497.	1.1	15
158	Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2015, 12, 93.	3.1	51
159	Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 1712-1721.	3.2	14
160	Haematological malignancies: at the forefront of immunotherapeutic innovation. <i>Nature Reviews Cancer</i> , 2015, 15, 201-215.	12.8	63
161	Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2061-2068.	2.0	87
162	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015, 17, vii32-vii40.	0.6	21
163	Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. <i>Cancer Gene Therapy</i> , 2015, 22, 487-495.	2.2	56
164	Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. <i>Clinical Cancer Research</i> , 2015, 21, 1835-1842.	3.2	58
165	Targeting the bone marrow microenvironment in multiple myeloma. <i>Immunological Reviews</i> , 2015, 263, 160-172.	2.8	323

#	ARTICLE	IF	CITATIONS
166	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. <i>Clinical Cancer Research</i> , 2015, 21, 2802-2810.	3.2	136
167	Lenalidomide induces apoptosis and inhibits angiogenesis via caspase-3 and VEGF in hepatocellular carcinoma cells. <i>Molecular Medicine Reports</i> , 2016, 14, 4781-4786.	1.1	15
168	Multiple myeloma, immunotherapy and minimal residual disease. <i>Neoplasma</i> , 2016, 63, 651-658.	0.7	1
169	Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role. <i>Journal of Immunology Research</i> , 2016, 2016, 1-7.	0.9	15
170	GM-CSF Down-Regulates TLR Expression via the Transcription Factor PU.1 in Human Monocytes. <i>PLoS ONE</i> , 2016, 11, e0162667.	1.1	38
171	The Role of Immunotherapy in Multiple Myeloma. <i>Pharmaceuticals</i> , 2016, 9, 3.	1.7	23
172	Atypical DRESS Syndrome Induced by Lenalidomide in Chronic Hemodialysis. , 2016, 6, .		0
174	How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4421-4430.	0.8	20
175	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. <i>Immunotherapy</i> , 2016, 8, 1393-1404.	1.0	8
176	The T Cell in Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 537-542.	0.2	43
177	Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review). <i>International Journal of Molecular Medicine</i> , 2016, 38, 1021-1029.	1.8	16
178	Targeting the Bone Marrow Microenvironment. <i>Cancer Treatment and Research</i> , 2016, 169, 63-102.	0.2	12
179	Indirect induction of regulatory T cells accompanies immune responses during peptide vaccination of chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2016, 174, 155-157.	1.2	1
180	Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q. <i>Annals of Hematology</i> , 2016, 95, 1805-1810.	0.8	11
181	New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5959-5965.	3.2	39
182	Current status of immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 191-203.	0.6	52
183	Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102 Td (	1.1	10
184	Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. <i>Oncolimmunology</i> , 2016, 5, e1115940.	2.1	66

#	ARTICLE	IF	CITATIONS
185	Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia. <i>Leukemia Research</i> , 2016, 40, 30-32.	0.4	7
186	Lenalidomide enhances myeloma-specific T-cell responses <i>in vivo</i> and <i>in vitro</i> . <i>OncImmunology</i> , 2016, 5, e1139662.	2.1	30
187	The safety of pomalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 535-547.	1.0	6
189	Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. <i>Leukemia Research</i> , 2016, 41, 56-61.	0.4	7
190	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 401-413.	1.9	175
191	Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation. <i>Clinical and Experimental Medicine</i> , 2017, 17, 193-207.	1.9	10
192	Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2017, 5, 2.	2.4	41
193	Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. <i>Drugs</i> , 2017, 77, 505-520.	4.9	150
194	Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 4290-4300.	3.2	192
195	Management of Uveitis and Scleritis in Necrobiotic Xanthogranuloma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 325-333.	0.6	6
196	Lenalidomide acts as an adjuvant for HCV DNA vaccine. <i>International Immunopharmacology</i> , 2017, 48, 231-240.	1.7	9
197	Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge?. <i>Bone Marrow Transplantation</i> , 2017, 52, 910-912.	1.3	4
198	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. <i>Seminars in Immunology</i> , 2017, 31, 64-75.	2.7	110
199	Immunotherapy based approaches in myelofibrosis. <i>Expert Review of Hematology</i> , 2017, 10, 903-914.	1.0	12
200	Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, 640.	2.8	19
201	Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. <i>Leukemia</i> , 2017, 31, 889-895.	3.3	16
202	Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. <i>Experimental Hematology</i> , 2017, 46, 48-55.	0.2	53
203	Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and ophthalmopathy (Review). <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 5251-5257.	0.8	16

#	ARTICLE	IF	CITATIONS
204	The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression. , 2017, , 33-61.		3
205	Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2017, 12, e0169736.	1.1	16
206	Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investigation, 2017, 4, 32-32.	1.3	59
207	Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. European Journal of Haematology, 2018, 101, 68-77.	1.1	13
208	Anti-cancer vaccine therapy for hematologic malignancies: An evolving era. Blood Reviews, 2018, 32, 312-325.	2.8	19
209	Next-generation immunotherapies for lymphoma: one foot in the future. Annals of Oncology, 2018, 29, 588-601.	0.6	13
210	Clinical Development of PD-1 Blockade in Hematologic Malignancies. Cancer Journal (Sudbury, Mass ), 2018, 24, 31-35.	1.0	11
211	Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia. Journal of Cancer Research and Clinical Oncology, 2018, 144, 449-457.	1.2	31
212	Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report. Transplantation Proceedings, 2018, 50, 873-876.	0.3	13
213	Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 311-320.	0.2	35
214	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Oncoimmunology, 2018, 7, e1316438.	2.1	42
215	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clinical Cancer Research, 2018, 24, 106-119.	3.2	136
216	Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Clinical Cancer Research, 2018, 24, 1002-1010.	3.2	30
217	Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase. Journal of Clinical Oncology, 2018, 36, 2101-2104.	0.8	8
218	Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. Oncotarget, 2018, 9, 20476-20489.	0.8	27
219	Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Frontiers in Immunology, 2018, 9, 2204.	2.2	45
220	“Holes” in the Jaw” A Report of Two Cases of Periapical Actinomycosis. Diseases (Basel, Switzerland), 2018, 6, 79.	1.0	4
221	Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study. Investigational New Drugs, 2018, 36, 1085-1092.	1.2	6

#	ARTICLE	IF	CITATIONS
222	Monocyte-Derived Dendritic Cells Differentiated in the Presence of Lenalidomide Display a Semi-Mature Phenotype, Enhanced Phagocytic Capacity, and Th1 Polarization Capability. <i>Frontiers in Immunology</i> , 2018, 9, 1328.	2.2	12
223	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 1370.	2.2	49
224	Update on the role of lenalidomide in patients with multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 175-190.	1.1	42
225	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 210-215.	1.4	2
226	&lt;p&gt;The immunomodulatory-drug, lenalidomide, sustains and enhances interferon- $\gamma$ production by human plasmacytoid dendritic cells&lt;/p&gt;. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 217-226.	0.7	9
227	Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071985417.	1.1	13
228	The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma. <i>Case Reports in Hematology</i> , 2019, 2019, 1-4.	0.3	0
229	Application of natural products derivatization method in the design of targeted anticancer agents from 2000 to 2018. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115150.	1.4	14
230	Lenalidomide improves the therapeutic effect of an interferon- $\gamma$ -dendritic cell-based lymphoma vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1791-1804.	2.0	18
231	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 921-928.	1.1	8
232	Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2258-2269.	1.9	5
233	Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 3171.	2.2	9
234	Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. <i>Oncimmunology</i> , 2019, 8, e1546544.	2.1	23
235	The Rationale for Immunotherapy in Myeloproliferative Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 310-327.	1.2	21
236	Elucidating the role of an immunomodulatory protein in cancer: From protein expression to functional characterization. <i>Methods in Enzymology</i> , 2019, 629, 307-360.	0.4	11
237	Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: A case series and review of the literature. <i>American Journal of Transplantation</i> , 2019, 19, 3185-3190.	2.6	15
238	Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens. <i>International Journal of Hematology</i> , 2019, 110, 306-312.	0.7	8
239	TNF $\gamma$ inhibitors as targets for protective therapies in MSA: a viewpoint. <i>Journal of Neuroinflammation</i> , 2019, 16, 80.	3.1	9

#	ARTICLE	IF	CITATIONS
240	Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. <i>Annals of Hematology</i> , 2019, 98, 1457-1466.	0.8	15
241	Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation. <i>Bioorganic Chemistry</i> , 2019, 87, 191-199.	2.0	35
242	T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 7-15.	2.0	37
243	Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. <i>Leukemia</i> , 2020, 34, 1563-1576.	3.3	17
244	Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells. <i>Cell Transplantation</i> , 2020, 29, 096368972092082.	1.2	27
245	Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms. <i>Dermatology</i> , 2020, 236, 467-476.	0.9	10
246	Actors on the Scene: Immune Cells in the Myeloma Niche. <i>Frontiers in Oncology</i> , 2020, 10, 599098.	1.3	51
247	Cytotoxic T Cell Responses Induced by CS1/CRT Fusion DNA Vaccine in a Human Plasmacytoma Model. <i>Frontiers in Oncology</i> , 2020, 10, 587237.	1.3	2
248	Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses. <i>Blood Advances</i> , 2020, 4, 3572-3585.	2.5	13
249	Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells. <i>Cancer Science</i> , 2020, 111, 2770-2778.	1.7	7
250	Daily alcohol intake triggers aberrant synaptic pruning leading to synapse loss and anxiety-like behavior. <i>Science Signaling</i> , 2020, 13, .	1.6	39
251	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 3837.	1.7	9
252	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	2.2	45
253	A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2020, 13, 435-445.	1.0	5
254	Immunotherapy in Multiple Myeloma. <i>Cells</i> , 2020, 9, 601.	1.8	27
255	Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. <i>Cancer Medicine</i> , 2020, 9, 1694-1702.	1.3	5
256	Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2020, 10, 636.	1.3	24
257	PD-L1â€“PD-1 Pathway in the Pathophysiology of Multiple Myeloma. <i>Cancers</i> , 2020, 12, 924.	1.7	41

#	ARTICLE	IF	CITATIONS
258	Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond. Expert Review of Hematology, 2020, 13, 669-686.	1.0	8
259	Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. Pediatric Blood and Cancer, 2021, 68, e28756.	0.8	9
260	Pomalidomide. Resistance To Targeted Anti-cancer Therapeutics, 2021, , 31-37.	0.1	1
261	Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Stem Cell Investigation, 2021, 8, 1-1.	1.3	17
262	Old and new generation immunomodulatory drugs in multiple myeloma. Panminerva Medica, 2021, 62, 207-219.	0.2	4
263	Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them. International Journal of Molecular Sciences, 2021, 22, 1103.	1.8	19
264	Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers, 2021, 13, 1353.	1.7	22
265	Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs. Frontiers in Immunology, 2021, 12, 632399.	2.2	30
266	Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. International Journal of Molecular Sciences, 2021, 22, 3302.	1.8	9
267	Boosting Immunity against Multiple Myeloma. Cancers, 2021, 13, 1221.	1.7	8
268	Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma. Blood Advances, 2021, 5, 2063-2074.	2.5	11
269	Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy. Blood Cancer Discovery, 2021, 2, 354-369.	2.6	37
270	Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. Journal of Hematology and Oncology, 2021, 14, 81.	6.9	149
271	Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics, 2021, 11, 1041.	1.3	3
273	Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients. Frontiers in Oncology, 2021, 11, 682658.	1.3	2
274	The Cancer-Immunity Cycle in Multiple Myeloma. ImmunoTargets and Therapy, 2021, Volume 10, 247-260.	2.7	11
275	The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma. Cancers, 2021, 13, 4090.	1.7	3
276	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer Journal, 2021, 11, 138.	2.8	103



#	ARTICLE	IF	CITATIONS
277	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4787.	1.7	14
278	Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity. <i>Cancers</i> , 2021, 13, 4867.	1.7	8
279	Immunotherapy in hematological malignancies: recent advances and open questions. <i>Immunotherapy</i> , 2021, 13, 1215-1229.	1.0	11
280	Upcoming immunotherapeutic combinations for B-cell lymphoma. <i>Immunotherapy Advances</i> , 2021, 1, .	1.2	3
281	Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF- $\alpha$ signaling factors. <i>International Journal of Biological Sciences</i> , 2021, 17, 926-941.	2.6	17
282	Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 215.	1.7	21
283	T Cell Responses in Myeloma. , 2013, , 3-24.		1
284	Myelodysplastic Syndromes (MDS). , 2010, , 153-222.		4
285	Lenalidomide. <i>Recent Results in Cancer Research</i> , 2014, 201, 347-357.	1.8	10
286	Immunotherapy of multiple myeloma. <i>Journal of Clinical Investigation</i> , 2020, 130, 1565-1575.	3.9	103
287	Developments in HIV-1 immunotherapy and therapeutic vaccination. <i>F1000prime Reports</i> , 2014, 6, 43.	5.9	14
288	Autologous Graft-Versus-Host Disease of the Gastrointestinal Tract in Patients With Multiple Myeloma and Hematopoietic Stem Cell Transplantation. <i>Gastroenterology Research</i> , 2018, 11, 52-57.	0.4	19
289	Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. <i>Oncotarget</i> , 2017, 8, 84847-84862.	0.8	7
290	Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. <i>Oncotarget</i> , 2017, 8, 27252-27262.	0.8	52
291	Lenalidomide overcomes the immunosuppression of regulatory CD8 <sup>+</sup> CD28 <sup>hi</sup> T-cells. <i>Oncotarget</i> , 2017, 8, 98200-98214.	0.8	15
292	Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2018, 9, 15780-15791.	0.8	4
293	Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments. <i>Current Medicinal Chemistry</i> , 2019, 26, 5244-5261.	1.2	8
294	Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma. <i>Current Cancer Drug Targets</i> , 2019, 19, 681-687.	0.8	13

#	ARTICLE	IF	CITATIONS
295	Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders Drug Targets, 2019, 19, 51-78.	0.2	15
296	Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies. , 2020, 2, 237-244.		3
297	Cancer Chemotherapy and Immune Regulation. American Journal of Immunology, 2009, 5, 8-16.	0.1	14
298	Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery. International Journal of Molecular Sciences, 2021, 22, 11378.	1.8	13
299	Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q. Cancers, 2021, 13, 5084.	1.7	7
300	Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment. Journal of Clinical Medicine, 2021, 10, 4588.	1.0	11
301	Clinical Trials of Antiangiogenesis Therapy on Gastric Cancer. Gastroenterology Research, 2008, 1, 14-19.	0.4	1
302	Regulatory T Cells in Cancer. , 2012, , 147-173.		0
303	Ongoing Clinical Trials in Myeloproliferative Neoplasms. , 2012, , 215-232.		0
304	Novel Therapies for T-cell Lymphomas. , 2013, , 297-305.		0
305	Managing Regulatory T Cells to Improve Cancer Immunotherapy. , 2013, , 281-314.		0
306	Defining Multiple Myeloma as a Target for DNA Vaccines. , 2013, , 73-110.		0
307	Newer IMiDs. , 2013, , 181-213.		0
308	New Agents for Multiple Myeloma. , 2014, , 131-140.		0
309	Adoptive T-Cell Transfer as a Clinical Antitumor Strategy for Hematologic Malignancies. , 2014, , 149-182.		0
310	Pooled Analysis of Pomalidomide for Treating Patients with Multiple Myeloma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3163-3166.	0.5	2
311	Pomalidomide for Treatment of Relapsed and Refractory Multiple Myeloma. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2015, 8, 379-389.	0.1	1
312	In Vitro Effect of Pomalidomide on Bone Marrow Mononuclear Cells From Multiple Myeloma Patients. Immunoregulation, 0, , 21-28.	0.1	0

#	ARTICLE	IF	CITATIONS
313	Standard care and investigational drugs in the treatment of myelofibrosis. <i>Drugs in Context</i> , 2019, 8, 1-16.	1.0	4
315	Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1720-1729.	2.3	1
316	IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors. <i>Cancer Letters</i> , 2022, 524, 121-130.	3.2	20
317	Cancer Immunoediting: Immunosurveillance, Immune Equilibrium, and Immune Escape. , 2020, , 291-305.		1
318	Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1185.	1.1	6
319	Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges. <i>Cells</i> , 2021, 10, 3309.	1.8	23
320	Clinical Courses of IKAROS and CTLA4 Deficiencies: A Systematic Literature Review and Retrospective Longitudinal Study. <i>Frontiers in Immunology</i> , 2021, 12, 784901.	2.2	4
321	The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2022, , 1-13.	1.3	2
322	Myeloma multiplex treatment and overall survival. <i>Makedonsko Farmaceutski Bilten</i> , 2022, 67, 79-90.	0.0	0
323	Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone. <i>Experimental Hematology</i> , 2022, 110, 60-68.	0.2	2
324	FDA-Approved Drugs for Hematological Malignanciesâ€”The Last Decade Review. <i>Cancers</i> , 2022, 14, 87.	1.7	38
333	Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release. <i>Journal of Clinical Medicine</i> , 2022, 11, 2720.	1.0	3
334	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5242.	1.8	7
335	Pathogenesis and treatment of multiple myeloma. <i>MedComm</i> , 2022, 3, .	3.1	8
336	Therapeutics to harness the immune microenvironment in multiple myeloma. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 647-61.	0.9	6
337	Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies. <i>Leukemia and Lymphoma</i> , 0, , 1-13.	0.6	1
338	Mechanisms of action of immunomodulatory drugs â€” from teratogenicity to treatment of multiple myeloma. <i>Gematologiya I Transfuziologiya</i> , 2022, 67, 240-260.	0.1	4
339	Multiple Myeloma Therapy: Emerging Trends and Challenges. <i>Cancers</i> , 2022, 14, 4082.	1.7	19

#	ARTICLE	IF	CITATIONS
340	Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	2
341	Bioequivalence of Pomalidomide Capsules in Fasting and Fed States in Healthy Male Volunteers: A Randomized, Open, Single-Dose, Biperiodic, Double-Crossover Study. <i>Clinical Pharmacology in Drug Development</i> , 0, , .	0.8	0
342	Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component. <i>Computational Biology and Chemistry</i> , 2022, 101, 107776.	1.1	3
343	Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents. <i>RSC Advances</i> , 2022, 12, 33525-33539.	1.7	13
344	Suspected Immune Thrombocytopenic Purpura Induced by Lenalidomide for the Treatment of Myelodysplastic Syndrome with Deletion of Chromosome 5q: A Case Report. <i>Tohoku Journal of Experimental Medicine</i> , 2022, , .	0.5	1
345	Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15879.	1.8	1
346	Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
347	Contribution of natural killer cells in innate immunity against colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
348	IMiDs Augment CD3-Bispecific Antibody-Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 659-666.	1.9	1
349	Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. <i>Pharmaceuticals</i> , 2023, 16, 415.	1.7	7
350	Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy. <i>Pharmaceutics</i> , 2023, 15, 1074.	2.0	3
353	Engraftment Syndrome Post Stem Cell Transplant. , 2023, , 833-837.		0
355	Metronomic Chemotherapy. , 2023, , 41-56.		0
358	What happens to regulatory T cells in multiple myeloma. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	0